PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
Imaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology wa...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2021/6654262 |
id |
doaj-d9de2023ef1b489ca1e41309948bcffc |
---|---|
record_format |
Article |
spelling |
doaj-d9de2023ef1b489ca1e41309948bcffc2021-06-21T02:24:24ZengHindawi LimitedBioMed Research International2314-61412021-01-01202110.1155/2021/6654262PET Imaging of CD8 via SMART for Monitoring the Immunotherapy ResponseLingyi Sun0Zhonghan Li1Yongyong Ma2Johannes Ludwig3Hyun S. Kim4Dexing Zeng5Center for Radiochemistry ResearchCenter for Radiochemistry ResearchCenter for Radiochemistry ResearchDepartment of Diagnostic and Interventional Radiology and NeuroradiologyDepartment of Radiology and Biomedical ImagingCenter for Radiochemistry ResearchImaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology was conducted. Mice bearing a subcutaneous colorectal CT26 tumor received three times different immunotherapy treatments (PD1 or CTLA4 or combined). On either day 7 or day 14 after the first time treatment, the PET imaging study was performed with sequentially administered TCO-modified anti-CD8 antibody and 64Cu-labeled MeTz-NOTA-RGD. However, no positive response was detected, probably due to (1) inappropriate selection of biomarkers for the SMART strategy, (2) limited TCO modification on the anti-CD8 antibody, and (3) inadequate response of the CT26 tumor to the selected immunotherapies. Therefore, the potential of applying SMART in imaging CD8 was not demonstrated in this study, and further optimization will be necessary before it can be applied in imaging CD8.http://dx.doi.org/10.1155/2021/6654262 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lingyi Sun Zhonghan Li Yongyong Ma Johannes Ludwig Hyun S. Kim Dexing Zeng |
spellingShingle |
Lingyi Sun Zhonghan Li Yongyong Ma Johannes Ludwig Hyun S. Kim Dexing Zeng PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response BioMed Research International |
author_facet |
Lingyi Sun Zhonghan Li Yongyong Ma Johannes Ludwig Hyun S. Kim Dexing Zeng |
author_sort |
Lingyi Sun |
title |
PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response |
title_short |
PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response |
title_full |
PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response |
title_fullStr |
PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response |
title_full_unstemmed |
PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response |
title_sort |
pet imaging of cd8 via smart for monitoring the immunotherapy response |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6141 |
publishDate |
2021-01-01 |
description |
Imaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology was conducted. Mice bearing a subcutaneous colorectal CT26 tumor received three times different immunotherapy treatments (PD1 or CTLA4 or combined). On either day 7 or day 14 after the first time treatment, the PET imaging study was performed with sequentially administered TCO-modified anti-CD8 antibody and 64Cu-labeled MeTz-NOTA-RGD. However, no positive response was detected, probably due to (1) inappropriate selection of biomarkers for the SMART strategy, (2) limited TCO modification on the anti-CD8 antibody, and (3) inadequate response of the CT26 tumor to the selected immunotherapies. Therefore, the potential of applying SMART in imaging CD8 was not demonstrated in this study, and further optimization will be necessary before it can be applied in imaging CD8. |
url |
http://dx.doi.org/10.1155/2021/6654262 |
work_keys_str_mv |
AT lingyisun petimagingofcd8viasmartformonitoringtheimmunotherapyresponse AT zhonghanli petimagingofcd8viasmartformonitoringtheimmunotherapyresponse AT yongyongma petimagingofcd8viasmartformonitoringtheimmunotherapyresponse AT johannesludwig petimagingofcd8viasmartformonitoringtheimmunotherapyresponse AT hyunskim petimagingofcd8viasmartformonitoringtheimmunotherapyresponse AT dexingzeng petimagingofcd8viasmartformonitoringtheimmunotherapyresponse |
_version_ |
1721369415289667584 |